Kyverna Therapeutics, Inc. (KYTX) vs ARS Pharmaceuticals, Inc. (SPRY)

Kyverna Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Kyverna Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($432.3M and $412.7M). Kyverna Therapeutics, Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 13 metrics below, Kyverna Therapeutics, Inc. leads on 12 and ARS Pharmaceuticals, Inc. on 1.

Valuation

Metric KYTX SPRY Biotechnology median
P/E n/m n/m 7.88
P/S n/m 3.47 11.47
P/B 2.51 32.38 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 3.70 10.73
Earnings yield (43.17%) (53.43%) (28.84%)
Free cash flow yield (38.34%) (52.35%) (23.03%)

Profitability

Metric KYTX SPRY Biotechnology median
Gross margin — 71.37% 65.16%
Operating margin 0.00% (184.96%) 0.00%
Net margin 0.00% (184.26%) 0.00%
Free cash flow margin 0.00% (167.97%) 0.00%
Return on equity (87.24%) (210.37%) (57.72%)
Return on assets (68.40%) (76.54%) (49.22%)
Return on invested capital 0.00% (335.65%) 0.00%

Growth

Metric KYTX SPRY Biotechnology median
Revenue growth (TTM) — 4.08% 5.64%
EPS growth (last fiscal year) (9.31%) (2,275.00%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KYTX SPRY Biotechnology median
Debt to equity 0.15 13.72 0.00
Current ratio 9.06 3.48 4.73
Net debt to EBITDA 1.51 0.42 0.96

Dividend

Metric KYTX SPRY Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric KYTX SPRY Biotechnology median
Market cap 432.29m 412.71m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack